Considerations in undertaking a clinical development program for Hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 1, 2010, Pages

  Talbot, George H ^a  

^a Talbot Advisors LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONFERENCE PAPER; CONFOUNDING VARIABLE; DRUG EFFICACY; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL AQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; DRUG APPROVAL; DRUG DEVELOPMENT; HOSPITAL; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG APPROVAL; DRUG DISCOVERY; HOSPITALS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

EID: 77955696914     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653064     Document Type: Conference Paper

References (14)

1. Basilea announces positive top-line data from phase III study of cef-tobiprole in hospital-acquired pneumonia. Basel, Switzerland, 9 Oc-tober 2007. http://www.basilea.com/News-and-media/?languagepen &yearp2007& searchpceftobiprole. Accessed 27 April 2009.
2. Maroko R, Cooper A, Dukart G, Dartois N, Gandjini H. Results of a phase 3 study comparing a tigecycline (TGC) regimen with an imi-penem/cilastatin (IMI) regimen in treatment of patients (pts) with hospital acquired pneumonia (HAP). In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). 17-20 September 2007. Abstract L-730.
3. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. Pharma-cokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated pneumonia studies: look before you leap! Clin Infect Dis 2010; 51(Suppl 1):S103-S110 (in this supplement).
4. Spellberg B, Talbot G; Infectious Diseases Society of America, American Thoracic Society, Society of Critical Care Medicine, American College of Chest Physicians. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. 2010; 51(Suppl 1): S150-S170 (in this supplement).
5. Talbot GH. Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients? Clin Infect Dis 2008; 47: S180-S185.
6. Center for Drug Evaluation and Research. Food and Drug Administration. Guidance for industry: community-acquired bacterial pneumonia: developing drugs for treatment. March 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm123686.pdf. Accessed 27 April 2009.
7. Andes DR, Craig WA. In-vivo pharmacodynamic activity of PPI-0903, a new cephalosporin prodrugs against multiple bacteria in murine thigh and lung infection models. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC). 30 October-2 November 2004. Paper A-1870.
8. Silverman JA, Mortia LI, VanPrangh ADG, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant In vitro modeling and clinical impact. J Infect Dis 2005; 191:2149-2152.
9. Gotfried MH, Shaw J-P, Benton BM, et al. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 2008; 52(1):92-97.
10. Lodise TP, Kinzig-Schippers M, Drusano GL, et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrob Agents Chemother 2008; 52:1945-1951.
11. Kikuchi E, Kikuchi J, Nasuhara Y, Oizumi S, Ishizaka A, Nishimura M. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother 2009; 53: 2799-2803.
12. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
13. Center for Drug Evaluation and Research, US Food and Drug Administration. Nosocomial pneumonia: developing antimicrobial drugs for treatment. July 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071170.pdf. Accessed 27 April 2009.
14. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.